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The Journal of Immunology
Enhancement of Tumor-Specific T Cell–Mediated Immunity
in Dendritic Cell–Based Vaccines by Mycobacterium
tuberculosis Heat Shock Protein X
In Duk Jung,*,1 Sung Jae Shin,†,1 Min-Goo Lee,‡ Tae Heung Kang,* Hee Dong Han,*
Seung Jun Lee,* Woo Sik Kim,† Hong Min Kim,† Won Sun Park,x Han Wool Kim,{,‖
Cheol-Heui Yun,{,‖ Eun Kyung Lee,# T.-C. Wu,**,††,‡‡,xx and Yeong-Min Park*
Despite the potential for stimulation of robust antitumor immunity by dendritic cells (DCs), clinical applications of DC-based immuno-
therapy are limited by the low potency in generating tumor Ag-specific T cell responses. Therefore, optimal conditions for generating
potent immunostimulatory DCs that overcome tolerance and suppression are key factors in DC-based tumor immunotherapy. In this
study, we demonstrate that use of the Mycobacterium tuberculosis heat shock protein X (HspX) as an immunoadjuvant in DC-based
tumor immunotherapy has significant potential in therapeutics. In particular, the treatment aids the induction of tumor-reactive T cell
responses, especially tumor-specific CTLs. The HspX protein induces DC maturation and proinflammatory cytokine production
(TNF-a, IL-1b, IL-6, and IFN-b) through TLR4 binding partially mediated by both the MyD88 and the TRIF signaling pathways.
We employed two models of tumor progression and metastasis to evaluate HspX-stimulated DCs in vivo. The administration of
HspX-stimulated DCs increased the activation of naive T cells, effectively polarizing the CD4+ and CD8+ T cells to secrete IFN-g, as
well as enhanced the cytotoxicity of splenocytes against HPV-16 E7 (E7)–expressing TC-1 murine tumor cells in therapeutic
experimental animals. Moreover, the metastatic capacity of B16-BL6 melanoma cancer cells toward the lungs was remarkably
attenuated in mice that received HspX-stimulated DCs. In conclusion, the high therapeutic response rates with tumor-targeted Th1-
type T cell immunity as a result of HspX-stimulated DCs in two models suggest that HspX harnesses the exquisite immunological
power and specificity of DCs for the treatment of tumors. The Journal of Immunology, 2014, 193: 1233–1245.
E
pidemiological studies analyzing the causes of cancer
often provide clues regarding effective prevention and
treatment methods. Indeed, the epidemiological research
investigating the bacillus Calmette–Gue´rin (BCG) vaccination
against tuberculosis (TB) and the occurrence of cancer has shown
a lower rate of occurrence of certain cancers in people who had
developed an effective level of immunity as a result of receiving
the BCG vaccine (1). Over the past 20 y, there has been contin-
uous research into cancer immunotherapy aimed at enhancing the
effects of innate immunity and CTLs using the BCG vaccine. In
particular, research is actively analyzing pathogen-associated
molecular patterns, the role of the pattern recognition receptors
known as TLRs, the cross-reactivity of Ags observed in cancer
and germs and viruses, and the development of adjuvants that
boost innate immune responses.
It is well known that dendritic cells (DCs) regulate the activity of
CTLs in innate and adaptive immune responses, which play crucial
roles in cancer immunotherapy (2). In addition, DCs are the APCs
in immunotherapy that can effectively present the Ag of a vaccine.
Recently, it has been reported that certain Ags of the BCG vaccine
can activate DCs through the TLR4 and TLR2 pathways and in-
crease the differentiation and activity of CTLs (3–7). Previously,
we reported an increase in the survival rate in an E.G7 thymoma
model in which mice were vaccinated with DCs, and heparin-
binding hemagglutinin protein extracted from Mycobacterium
tuberculosis was used to stimulate the TLR4 levels (6). M. tu-
berculosis consists of various proteins that are involved in the
maturation and activation of DCs, and during a screen for DC
activators within the mycobacterial Ag, we identified heat shock
protein X (HspX) as the strongest TLR4 agonist.
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The 16-kDa HspX (Rv2031c) is required for mycobacterial
persistence within the macrophage and is a dominant protein
produced during static growth or under hypoxic conditions (8). The
immunogenicity of HspX in BALB/c and C57BL/6 mice immu-
nized with DNA plasmids encoding hspX was demonstrated by the
induction of strong HspX Ag-specific Th1-type cytokine secretion
and Ab production (9). In addition, IFN-g responses to HspX were
significantly higher in M. tuberculosis–exposed individuals than in
M. tuberculosis–unexposed BCG vaccinees (10). However, very
little is known about how HspX elicits host immune responses.
HspX is reported to be a promising candidate for TB vaccines
owing to the induction of Th1-type T cell immunity. We believe
that HspX boosts host immunity against M. tuberculosis by
interacting with DCs as a TLR ligand. Thus, we speculate that
HspX can ultimately be used as a key adjuvant in cancer thera-
peutic vaccination, especially in the context of DC-based immu-
notherapy.
In this article, we describe the biological activity and cellular
immunity of M. tuberculosis HspX in DC-based CTL activation,
as well as its potential as an adjuvant in DC-based antitumor
immunotherapy. We show that HspX is a potent TLR4 agonist that
can enhance both DC activation and Th1 polarization through the
MyD88 and TRIF signaling pathways. Notably, HspX mediated
a strong induction of Ag-specific CD8+ T cell–mediated immune
responses, leading to the regression of tumor growth and metas-
tasis in vivo. These results open the door to promising possibilities
for the use of HspX as a potential adjuvant for DC-based antitu-
mor immunotherapies.
Materials and Methods
Mice
Male 6- to 8-wk-old C57BL/6 (H-2Kb and I-Ab) mice were purchased from
the Korean Institute of Chemistry Technology (Orient, Daejeon, Korea).
C57BL/6 OT-I and C57BL/6 OT-II TCR transgenic mice, C57BL/6J TLR2
knockout mice (TLR22/2; B6.129-Tlr2tm1Kir/J), C57BL/10 TLR4 knock-
out mice (TLR42/2; C57BL/10ScNJ), MyD88 knockout mice, and TRIF-
deficient mice aged 6–8 wk were purchased from The Jackson Laboratory
(Bar Harbor, ME). They were housed in a specific pathogen–free envi-
ronment within an animal facility for $1 wk before the experiment, and
used in accordance with the institutional guidelines for animal care (In-
stitutional Animal Care and Use Committee number: KU13047).
Cell lines. Primary C57BL/6 mouse lung epithelial cells were cotrans-
formed with HPV-16 E6 and E7, and an activated ras oncogene to generate
the TC-1 cells, as previously described (11). TC-1 cells were cultured in
RPMI 1640 supplemented with 10% heat-inactivated FBS, 100 U/ml
penicillin, 100 mg/ml streptomycin, and 10 mM L-glutamine (all pur-
chased from Invitrogen, Carlsbad, CA) at 37˚C with 5% CO2.
Reagents and Abs
Recombinant mouse GM-CSF, IL-4, CCL19, and the FITC–Annexin V/pro-
pidium iodine kit were purchased from R&D Systems (Minneapolis, MN).
Dextran-FITC (40,000 Da) was purchased from Sigma-Aldrich (St. Louis,
MO). LPS (from Escherichia coli O111:B4) was purchased from Invivogen
(San Diego, CA). H-2Kb–restricted OVA peptide (OVA257–264), H-2D
b–re-
stricted OVA peptide (OVA323–339), and HPV-16 E7 (aa 49–57) peptide
(RAHYNIVTF) were synthesized by Peptron (Daejeon, Korea). The following
FITC- or PE-conjugated mAbs were purchased from BD Biosciences (San
Jose, CA): CD8 (SK17), CD11c (HL3), CD62L (MEL14), CD80 (16-10A1),
CD83 (Michel-17), CD86 (GL1), Iab b-chain (AF-120.1), H-2Kb (AF6-88.5),
CCR7 (CD197), IL-10 (JESS-16E3), and IL-12p40/p70 (C15.6). Alexa 568–
conjugated anti-mouse IgG Abs were purchased from Invitrogen (Eugene,
OR). FITC-conjugated mouse IgG Abs and cytokine ELISA kits for murine
IL-1b, IL-2, IL-6, IL-10, IL-12p70, TNF-a, IFN-b, and IFN-g were pur-
chased from eBiosciences (San Diego, CA).
Expression and purification of recombinant HspX protein
The recombinant HspX protein was produced using the pET28a (Promega,
Madison, WI) vector and E. coli expression system, as recently described
(6). Briefly, rv2301c encoding HspX was amplified by PCR using M. tu-
berculosis H37Rv genomic DNA (ATCC 27294) as a template and the
following primers: forward, 59-GGG CCC GGA TCC ATG GCA AAG
CTC TCC-39; and reverse, 59-GGG CCC GAATTC CTT GAC GGT GAC
GGT-39. The PCR product was cut using BamHI and EcoRI, and then
inserted into the pET28a vector, which was cut with the same restriction
enzymes. The recombinant plasmid was transformed into E. coli BL21
cells carrying bacteriophage DE3 for protein overexpression.
DC generation and culture. DCs were generated from murine bone marrow
cells according to the procedure of Inaba et al. (12), with minor mod-
ifications. In brief, bone marrow was flushed from the tibias and femurs of
6- to 8 wk-old male C57BL/6 mice and depleted of RBCs using RBC
Lysing Buffer (Sigma-Aldrich). The cells were plated in six-well culture
plates (1 3 106 cells per milliliter; 3 ml per well) in RPMI 1640 supple-
mented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 mg/ml
streptomycin, 20 ng/ml recombinant mouse (rm)GM-CSF, and 10 ng/ml
rmIL-4 at 37˚C in 5% CO2. On days 3 and 5 of culturing, floating cells
were gently removed and fresh medium was added. On day 6 of the cul-
ture, nonadherent cells and loosely adherent proliferating DC aggregates
were harvested for analysis or stimulation. On day 7, $90% of the non-
adherent cells expressed CD11c.
Determination of affinity value of the binding of TLR4 and HspX. The
binding between rmTLR4/MD2 and HspX was performed using the BLItz
system (ForteBio, Menlo Park, CA). Human rTLR4/MD2 tagged with anti–
penta-His (HIS) was purchased from R&D Systems (Minneapolis, MN).
HIS biosensors (catalog no. 18-5078, Fortebio) were hydrated for 10 min
prior to the experiment. The concentration of HIS-tagged rmTLR4/MD2
was 0.1 mg/ml, and that of both purified HspX and BSA, Pam3CSK4, and
LPS was 2 mg/ml. The setting was as follows: initial baseline for 30 s,
loading for 300 s, baseline for 60 s, association for 300 s, and dissociation
for 300 s. The affinity value of HspX was generated by BLItz pro software
analysis as a nonadvanced kinetics experiment.
Antigen uptake and migration of DCs
Ag uptake and in vitro and in vivo chemotaxis were performed as previously
described (6).
DC migration in vitro and in vivo. DC migration was assayed by a modi-
fication of the Boyden chamber method (13) performed in a microche-
motaxis chamber (NeuroProbe, Gaithersburg, MD) using a polycarbonate
membrane (NeuroProbe) with a pore size of 5.0 mm. The membranes were
coated with mouse type IV collagen (20 mg/ml in PBS) and placed be-
tween the chambers. First, the lower well of the chamber was filled with 27
ml RPMI 1640 supplemented with 0.1% BSA following the addition of
CCL19 at the indicated concentration. The DCs were washed with RPMI
1640 containing 0.1% BSA resuspended at a concentration of 13 106 cells
per milliliter in RPMI 1640 supplemented with 0.1% BSA. The cells were
then placed in the upper well of the chamber (50 ml per well) and incu-
bated at 37˚C in 95% air and 5% CO2 for 2 h. At the end of the incubation,
the filters were removed and all nonmigrated cells on the upper side of
the filter were scraped off with wet tissue paper. The migrated cells on the
other side of the filter were fixed for 2 min with fixative solution from the
HEMA 3 stain set and stained with solutions 1 and 2 of the HEMA 3 stain
set, each for 2 min (Fisher Scientific, Kalamazoo, MI). The numbers of
stained cells were quantified densitometrically using IMAGE GAUGE
Version 2.54 (Fujifilm) for data analysis. For the in vivo migration test,
DCs were labeled with 0.5 mM CFSE (Molecular Probes, Eugene, OR).
Labeled cells (13 106) were injected s.c. in the hind-leg footpad. Popliteal
lymph nodes (LNs) were removed 72 h later, mechanically disaggregated,
and treated with collagenase A (1 mg/ml; Boehringer Mannheim, Indi-
anapolis, IN) and DNase (0.4 mg/ml; Roche, Indianapolis, IN) for 30 min.
The enzymatically treated cell suspension was evaluated for the number of
CFSE+ DCs by flow cytometry.
MLR. DCs were incubated with HspX or LPS in the presence or absence
of OVA257–264 (0.5 mg/ml), OVA323–339 (0.5 mg/ml), or HPV 16-E7 peptide
(1 mg/ml) for 24 h. CFSE-labeled OT-I T cells (for OVA257–264), OT-II
T cells (for OVA323–339), and naive T cells (for HPV 16-E7 peptide) were
seeded in triplicate wells (1 3 105 cells per well) in U-bottom, 96-well
microtiter culture plates (Nunc), together with DCs (1 3 104 cells per
well). Cells were harvested after 96 h, stained with Cy5-labeled anti-CD8
and anti-CD4 mAb, and analyzed by flow cytometry (Becton Dickinson,
San Jose, CA).
Tumor protection assay. Mice were s.c. injected with TC-1 (2 3 106) cells
in the right lower back, followed by a footpad injection with PBS, DCs, or
HspX-treated DCs (1 3 106 cells per mouse) pulsed with or without HPV
16-E7 peptide (1 mg/ml) on days 1, 3, and 5 after tumor inoculation.
Groups of tumor-bearing mice were treated with PBS, DCs, DCs pulsed
with E7 peptide (E7-DCs), or HspX-treated DCs pulsed with E7 peptide
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(HspX-E7-DCs). Tumor size was measured every 2 d, and the tumor mass
was calculated as V = (2A 3 B)/2, where A is the length of the short axis
and B is the length of the long axis.
Lung metastasis assay.Murine B16-BL6 melanoma cells were injected into
the tail vein (3 3 105 cells per mouse). The hind leg footpads of the mice
were then injected with PBS, DCs, or HspX-treated DCs (13 106 cells per
50 ml per mouse) pulsed with or without H-2 Kb–restricted TRP2 peptide
(aa 180–188, 1 mg/ml) on days 1, 3, and 7 of the posttumor injection. At 1
wk after the final immunization, the lungs were removed from these mice,
and the metastatic nodules were quantified.
In vivo CTL assay
Mice were injected with PBS, DCs, DCs pulsed with E7-DCs, or HspX-E7-
DCs on days 1 and 7. At 7 d after the last immunization, the splenocytes from
the syngeneic mice were pulsed with or without HPV-16 E7 peptide (10 mg/
ml) for 45 min at 37˚C. Then, the HPV-16 E7 peptide pulsed and unpulsed
populations were loaded with either 5 mM (high) or 0.5 mM (low) CFSE
(Molecular Probes) at 37˚C for 10 min. The two populations were mixed 1:1
before tail vein injection into the immunized mice (107 cells per mouse). At
4 h after the injection, the splenocytes were isolated, and the number of
CFSEhigh and CFSElow populations was measured by flow cytometry.
Statistical analysis
Statistical significance was assessed by the Student paired t test. A p value,
0.05 was considered statistically significant. Survival data were analyzed by
the Kaplan–Meier log-rank test. Statistical analysis was conducted using
Prism 4 GraphPad software (San Diego, CA).
Results
HspX enhances the maturation of functional DCs
HspX protein was carefully purified from soluble recombinant
HspX (rRv2031) expressed in E. coli under endotoxin-free ex-
perimental conditions. However, we were concerned that the
HspX may have been contaminated with endotoxin derived from
the cell wall of E. coli, as it is a well-known factor of DC mat-
uration. Therefore, we confirmed the purity and lack of endotoxin
contamination of E. coli–derived HspX using the LAL endotoxin
assay kit (GenScript USA) and immunoblot with the anti-histidine
Ab. The levels of endotoxin in HspX were ,15 pg/ml (,0.1 EU/
ml), and the molecular mass of purified HspX was ∼16 kDa
(Supplemental Fig. 1A). In addition, proteinase K–treated or heat-
treated HspX was unable to promote the production of secreted
TNF-a and IL-6 in DCs. HspX was resistant to polymyxin B
treatment, which is an inhibitor of LPS function (Supplemental
Fig. 1B). We next investigated whether HspX affected DC via-
bility and found that HspX-treated DCs showed no effect up to
500 ng/ml (Supplemental Fig. 1C).
After checking the safety of HspX in DCs, we measured the
expression levels of surface molecules that are markers for DC
maturation, including CD80, CD83, CD86, andMHC class I and II,
on DCs following HspX stimulation. The upregulation of surface
molecules on DCs following HspX stimulation occurred in a dose-
dependent manner (Fig. 1A). Next, the levels of proinflammatory
and anti-inflammatory cytokine secretion following stimulation of
DCs with HspX were investigated. As shown in Fig. 1B, the levels
of TNF-a, IL-6, IL-1b, and IFNb were significantly induced in
HspX-treated DCs (Fig. 1Ba). In addition, the levels of IL-12p70
in the HspX-treated DCs were significantly increased, whereas the
levels of IL-10 were not altered. This finding indicates that HspX
could be used as an adjuvant for the induction of a Th1 immune
response (Fig. 1Bb). We reconfirmed the level of intracellular
IL-12p70 and IL-10 production in HspX-treated DCs, and showed
that IL-12p70+ DCs increased only by HspX stimulation
(Supplemental Fig. 2). In addition, the capacity of Ag (dextran)
uptake, which decreases during DC maturation after Ag recogni-
tion, in HspX-treated DCs significantly decreased in a similar
fashion to that observed in the LPS treatment (Fig. 1C). These
results indicate that HspX phenotypically and functionally acti-
vated DCs to promote Th1 immune responses.
HspX induces migration of DCs
Because CCR7 is an important factor for the migration of DCs to
lymphoid organs (14, 15), the increased levels of CCR7 expression
in HspX-treated DCs were confirmed (Fig. 2A). We also used an
in vitro Transwell migration assay to analyze the DC migratory
capacity in response to chemokine ligand 19 (CCL19), which is
the ligand for CCR7. An increase in the migration of DCs was
observed in the HspX-treated DCs (Fig. 2B), which is consistent
with the upregulation of CCR7 expression.
To further confirm the migratory capacity of DCs in response to
HspX stimulation, we investigated the number of CFSE+ DCs in the
draining LNs in vivo. The number of CFSE+ DCs in the draining
LNs was significantly increased in the HspX-treated groups com-
pared with those without HspX treatment (Fig. 2C). Therefore,
these results demonstrate that HspX promotes DC migration in vitro
and in vivo, and suggest that the Ag-specific T cell response is
enhanced in HspX-treated DCs.
HspX enhances the maturation of functional DCs via
a TLR4-dependent pathway
Next, using TLR22/2 and TLR42/2 mice, we investigated which
TLRs are crucial in HspX-mediated maturation of DCs. The ex-
pression of surface molecules (CD86 and MHC class II) was en-
hanced in HspX-treated WT and TLR22/2 DCs, whereas these
effects were significantly abrogated in TLR42/2 DCs (Fig. 3A). Of
interest, neither HspX nor LPS (a TLR4 agonist) enhanced the
secretion of proinflammatory cytokines (TNF-a, IL-6, and IL-1b)
in DCs from TLR42/2 mice. These results indicate that TLR4
mediation is critical for DC maturation by HspX (Fig. 3B).
Furthermore, to determine whether HspX directly bound to
TLR4, we measured the direct binding of TLR4 with HspX using
the BLItz system. HIS-tagged recombinant TLR4/MD2 was
labeled with an anti–penta-HIS biosensor. After washing away
the loosely bound TLR4/MD2, association was initiated by
dipping the TLR4-tagged HIS biosensor in solutions of BSA
(negative control), Pam3CSK4, LPS, HspX, or PBS, and then
monitored in real time. Dissociation was initiated by dipping the
same biosensor into PBS and was then monitored in the same
manner. The calculated values of Ka, Kd, and KD between HspX
and TLR4 were 6.677e5 (1/Ms), 3.433e23 (1/S), and 5.14 e29
(M), respectively (Fig. 3C). Comparatively, BSA (a non-TLR
agonist) and Pam3CSK4 (a TLR2 agonist) did not bind TLR4.
These results indicate that HspX has a strong binding affinity to
TLR4/MD2.
The MyD88 and TRIF signaling pathways are involved in
Hspx-induced maturation of DCs
Toll/IL-1 receptor domain–containing adaptors such as MyD88
and TRIF are key modulators in TLR4-mediated intracellular
signaling pathways. To investigate the involvement of the MyD88
and TRIF signaling pathways in the production of proinflammatory
cytokines, we measured proinflammatory cytokine production in
DCs derived from WT, MyD882/2 mice, or TRIF-deficient mice
exposed to HspX or LPS. The production of TNF-a, IL-1b, and
IL-6 in both the HspX-treated DCs and LPS-treated DCs was
significantly diminished in the absence of MyD88 or TRIF
(Fig. 4A).
Among the earliest events following TLR4 ligation is its as-
sociation with the adaptor proteinsMyD88 and TRIF, both of which
initiate distinct signaling pathways (16). To confirm whether HspX
directly activated TLR4 and the downstream TLR4 signals, we
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performed an immunoprecipitation assay and a Western blot assay.
HspX activated the tyrosine phosphorylation of TLR4 (Fig. 4Ba) and
then enhanced the interaction of MyD88 and IRAK4 (Fig. 4Bb). In
addition, HspX activated the phosphorylation of IFN response factor
3 (IRF3), which is a transcription factor for the induction of IFN-b
in the TRIF-mediated signaling cascade (Fig. 4Bc).
Furthermore, we investigated three downstream pathways of
MyD88, namely, MAPKs, NF-kB, and PI3K/PDK1/Akt (17) (18),
which promote TLR4-mediated proinflammatory cytokine pro-
duction in DCs stimulated by HspX. We found that HspX en-
hanced the phosphorylation of MAPKs such as ERK, JNK, and
p38MAPK (Fig. 4C), activated NF-kB regulated by IKKa/b and
IkBa (Fig. 4D), and enhanced TLR4-mediated PDK1 and Akt
phosphorylation (Fig. 4E). Taken together, these findings suggest
that TLR4-mediated MyD88-dependent and TRIF-dependent
pathways are crucial for optimal HspX-induced DC activation.
HspX enhances naive T cell proliferation and Th1 polarization
via DC activation
The major roles of mature DCs are Ag presentation, interaction
with T cells, and subsequent T cell activation. To clarify the effect
of HspX on DC and T cell interactions, we performed a syngeneic
MLR assay using OT-I TCR transgenic CD8+ T cells and OT-II
TCR transgenic CD4+ T cells (19). The CFSE-labeled OVA-
specific CD4+ and CD8+ T cells proliferated in and cocultured
with DCs presenting OVA257–264 (Fig. 5Aa) or OVA323–339
(Fig. 5Ab), which was significantly potentiated by HspX treatment
(Fig. 5A). Furthermore, the production of IFN-g by the activated
T cells was also significantly enhanced by HspX (Fig. 5B).
Combining these results with the IL-12p70 production of DCs
(Fig. 1Bb), we propose that HspX-treated DCs could be used in
cancer immunotherapy to polarize naive CD4+ and CD8+ T cells
toward an IFN-g–producing Th1-type T cell phenotype.
FIGURE 1. HspX enhances the phenotypical and functional maturation of DCs. (A) DCs were treated with the indicated concentrations of HspX or LPS
for 24 h. Flow cytometry was used to analyze the expression of surface molecules on the CD11c+ cells. The mean fluorescence intensity and the percentage
of positive cells are shown in each panel. The results of one representative experiment (n = 5) are shown. (B) DCs were treated with the indicated
concentrations of HspX or LPS (50 ng/ml) for 24 h. ELISAs were performed to test the IL-12p70, IL-10, TNF-a, IL-6, IL-1b, and IFN-b production in
HspX-treated and LPS-treated DCs. Data are the mean and SEM (n = 3). *p , 0.05, **p , 0.01, ***p , 0.001 compared with untreated DCs (CON) (Ba
and Bb). (C) Endocytic activity of HspX-treated versus untreated DCs (CON). Endocytic activity at 37˚C or 4˚C was assessed by flow cytometry analysis as
dextran-FITC uptake. The percentages of dextran-FITC+CD11c+ cells are shown. The results of one representative experiment (n = 5) are shown.
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We performed a syngeneic MLR assay using cervical tumor–
specific Ag E7 peptide to check whether HspX has immunoadju-
vanticity in cancer vaccination against virtual cervical cancer.
Although CFSE-labeled CD8+ (Fig. 5Aa) or CD4+ (Fig. 5Ab)
T cells proliferated in coculture with DCs presenting E7 peptide,
these T cells also significantly proliferated in HspX-treated DCs
(Fig. 5C). IFN-g production by activated T cells was also signifi-
cantly enhanced by HspX treatment (Fig. 5D). We next analyzed the
differentiation of CD4 T cells by HspX-activated DCs, measuring
through the intracellular cytokine staining and transcription factor
(TCF) staining. As shown in Fig. 6, we investigated whether HspX-
treated DCs increased the levels of a Th1-type cytokine, IFN-g, and
a Th1-type transcriptional factor, T-bet; however, Th2- and Th17-
type cytokines, IL-4 and IL-17A, and GATA-3 (TCF for Th2) and
RoRgt (TCF for Th17) did not. In summary, DCs activated by
HspX elevate the proliferation of CD4+ and CD8+ T cells and
differentiate CD4+ T cells toward Th1 immunity.
HspX enhances the efficacy of DC-based antitumor
immunotherapy against a cervical cancer model
The above results of enhanced tumor Ag (E7)–specific T cell
proliferation by HspX (Fig. 5C, 5D) motivated us to test the ef-
fect of HspX on DC immunotherapy in an in vivo model of cer-
vical cancer. Injection of E7-DCs significantly inhibited TC-1
tumor growth compared with mice receiving PBS or immature
DCs (Fig. 7A). Of Interest, injection of HspX-E7-DCs reduced the
TC-1 tumor growth further than that achieved by E7-DC injections
(Fig. 7A). Notably,.60% of the mice injected with the HspX-E7-
DCs survived beyond 60 d following the TC-1 tumor implanta-
tion, whereas only 20% of the mice injected with E7-DCs survived
during the same period. All the mice in the PBS and DC-injected
groups died within 46 d after tumor implantation (Fig. 7B).
To assess whether activated CD8+ T cells among splenocytes in
the tumor model were enhanced by HspX-E7-DCs, we measured
the surface expression levels of CD62L and CD44, which promote
CD8+ T cell migration to the site of Ag deposition (6). Although
the number of activated CD8+ T cells (CD62LlowCD44high) from
the mice injected with E7-DCs (21% of CD44 and 34% of
CD62L) was enhanced compared with that of mice injected with
either PBS (5% of CD44 and 54% of CD62L) or DCs (7% of
CD44 and 51% of CD62L), the number of activated CD8+ T cells
from mice injected with HspX-E7-DCs (32% of CD44 and 15% of
CD62L) was significantly higher than that of mice injected with
E7-DCs (Fig. 7C).
Finally, we determined the ability of activated CD8+ T cells stim-
ulated by HspX-E7-DCs to kill tumor cells using an in vivo CTL
activity assay. We found that a significantly high level of target cell
lysis was observed in mice that received HspX-E7-DCs (54.2 6
0.35%) compared with those that received PBS (0 6 0.05%), DCs
(0.1 6 0.04%), or E7-DCs (22.3 6 0.28%) (Fig. 7D). These results
indicate that HspX could be a crucial factor for cancervaccine against
E7+ cervical tumor by enhancing killing activity to target cells.
HspX enhances the efficacy of DC-based antitumor
immunotherapy against the B16-BL6 pulmonary metastasis
model
Tumor immunotherapy using DC vaccination was expected to be
effective in the prevention of metastasis and recurrence of the
primary tumor, as well as in regression of the primary tumor mass.
Therefore, we determined whether HspX-treated DCs pulsed with
FIGURE 2. HspX enhances the migration of
DCs in vitro and in vivo. (A) DCs were treated with
the indicated concentrations of HspX or LPS for
24 h. The percentage of CCR7+CD11c+ DCs was
analyzed by flow cytometry. The number in each
panel indicates the percentage of positive cells. A
representative experiment (n = 5) is shown. (B) DCs
were treated with HspX or LPS for 24 h and then
subjected to an in vitro Transwell chemotaxis assay
in which movement toward medium alone or me-
dium containing CCL19 (300 ng/ml) was mea-
sured. (C) CFSE-labeled HspX-treated or LPS-
treated DCs were s.c. injected into the hind leg
footpad of mice, and the cells were recovered from
popliteal LNs 72 h later and analyzed. ***p ,
0.001 compared with untreated DCs (control).
The Journal of Immunology 1237
 at Y
onsei M
edical Library on D
ecem
ber 8, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
tumor lysate of B16-BL6 (TL) and TRP2, which is a tumor-
associated Ag of B16-BL6, have anti–B16-BL6 pulmonary me-
tastasis effects, using a therapeutic protocol. B16-BL6 metastatic
nodules in the lungs were reduced by immunization with TL-
pulsed DCs (Fig. 8A) or TRP2 peptide–pulsed DCs (Fig. 8B).
They were further reduced by immunization with TL-pulsed
HspX-treated DCs or TRP2 peptide–pulsed HspX-treated DCs
(Fig. 8). These data indicate that HspX-treated DCs have an in-
hibitory effect on B16-BL6 pulmonary metastasis.
Discussion
In this study, we focused onM. tuberculosis HspX, which has been
used as an effective adjuvant for BCG vaccination (20). The
finding that it potentiated the CTL immune response in TB vac-
cination supports its application in cancer vaccinations. We found
that HspX was a highly selective agonist of TLR4 in DCs. HspX
strongly bound to TLR4 in the BLItz assay and activated the
TLR4 signaling pathway. This study also showed enhanced ex-
pression of CD86 and MHC class II and the production of
FIGURE 3. HspX induces the phenotypical and functional maturation of DCs by binding to TLR4. (A) DCs derived from WT, TLR22/2, and TLR42/2
mice were treated with HspX (500 ng/ml) or LPS (50 ng/ml) for 24 h. Flow cytometry was used to analyze the expression of the surface molecules CD86
and MHC class II on the CD11c+ cells. The percentage of positive cells is shown in each panel. The results of one representative experiment (n = 5) are
shown. (B) DCs derived from WT, TLR22/2, and TLR42/2 mice were treated with Pam3CSK4 (TLR2 agonist, 10 mg/ml), LPS (TLR4 agonist, 50 ng/ml),
imiquimod (TLR7 agonist, 1 mg/ml), ODN1826 (TLR9 agonist, 10 mg/ml), or HspX (500 ng/ml) for 24 h. ELISAs were performed to test TNF-a, IL-6, and
IL-1b production in HspX agonist–treated or TLRs agonist–treated DCs. Data are mean and SEM (n = 3). ***p , 0.001 compared with WT cultures. (C)
The BLItz system results for the interaction of rmTLR4/MD2 with HspX (red line), positive control (LPS = blue line), and negative control (BSA = purple
line, Pam3CSK4 = green line, or PBS = black line) are shown. The vertical and horizontal axes represent the light shift distance (nm) and association/
dissociation time (sec), respectively. The affinity value, KD, was calculated from the association and dissociation curves of HspX.
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FIGURE 4. HspX-induced cytokine production is mediated by both the MyD88 and TRIF pathways. (A) DCs derived from WT, MyD882/2, and TRIF-
deficient mice were treated with the indicated concentrations of HspX or LPS for 24 h. The supernatants were harvested and ELISAs were performed to test
TNF-a, IL-6, and IL-1b production. Data are the mean and SEM (n = 3). *p , 0.05, **p , 0.01, ***p , 0.001 compared with WT cultures. (B) DCs were
treated with HspX (500 ng/ml) at the indicated time points. The cells were harvested, and the cell lysates (1 mg) were immunoprecipitated with anti-TLR4.
The immunoprecipitated proteins were visualized by immunoblot with anti–p-Tyr or anti-TLR4 Abs (a). The cells were harvested, and the cell lysates
(1 mg) were immunoprecipitated with anti-IRAK4. The immunoprecipitated proteins were visualized by immunoblot with anti-MyD88 or anti-IRAK4 Abs
(b). The cells were harvested, and the cell lysates were visualized by immunoblot with anti–p-IRF3 or anti-IRF3 Abs (c). (C) DCs were treated with HspX
(500 ng/ml) at the indicated time points. The cells were harvested, and the cell lysates were visualized by immunoblot with anti–p-ERK, anti-ERK, anti–p-
p38MAPK, anti-p38MAPK, anti–p-JNK, or anti-JNK Abs. (D) DCs were treated with HspX (500 ng/ml) at the indicated time points. The cells were
harvested, and the cell lysates were visualized by immunoblot with anti–p-IKKa/b, anti-IkBa, anti-p65, or anti–a-tubulin Abs. (E) DCs were treated with
HspX (500 ng/ml) at the indicated time points. The cells were harvested, and the cell lysates were visualized by immunoblot with anti-p-PDK1, anti-PDK1,
anti–p-Akt, or anti–Akt Abs.
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FIGURE 5. HspX-treated DCs induce proliferation of
CD4+ and CD8+ T cells and a Th1 response. (A) Transgenic
OVA-specific CD8+ T cells (a) and OVA-specific CD4+
T cells (b) were isolated and stained with CFSE and
cocultured for 96 h with untreated DCs, DCs pulsed with
OVA257–264, HspX (500 ng/ml)–treated DCs pulsed with
OVA257–264, or LPS (50 ng/ml)–treated DCs pulsed with
OVA257–264. T cell proliferation was assessed by flow
cytometry, and the percentage of proliferating cells is
shown in each panel. A representative experiment (n = 3) is
shown. (B) At 24 h after culture, IFN-g production was
measured in the supernatant by ELISA. ***p , 0.001
compared with the value from T cell/OVA peptide–pulsed
DCs. (C) T cells were isolated and stained with CFSE,
cocultured for 96 h with untreated DCs, DCs pulsed with
E7 peptide, HspX (500 ng/ml)–treated DCs pulsed with E7
peptide, or LPS (50 ng/ml)–treated DCs pulsed with E7
peptide, and then stained with anti-PE/Cy5–conjugated
CD4 or CD8 Abs. T cell proliferation was assessed by flow
cytometry, and the percentage of proliferating cells is shown
in each panel. A representative experiment (n = 3) is shown.
(D) At 24 h after culture, IFN-g production was measured in
the supernatants by ELISA. ***p , 0.001 compared with
the value from T cell/E7 peptide–pulsed DCs.
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FIGURE 6. HspX-treated DCs stimulate T cells to Th1, but not Th2 or Th17. Transgenic OVA-specific CD4+ T cells were isolated and cocultured for
72 h with DCs treated with HspX (500 ng/ml) or LPS (50 ng/ml), then pulsed with OVA323–339 (1 mg/ml) to produce OVA-specific CD4
+ T cells. T cells
alone and T cells cocultured with untreated DCs served as controls. The graphs show intracellular cytokine production (A) and transcription factors (B) in
CD3+/CD4+. (A) IFN-g, IL-4, or IL-17A expression in CD3+/CD4+ was analyzed in T cells. (B) T-bet, GATA-3, and RORgt expression in CD3+/CD4+ cells
was assessed by intracellular staining. ***p , 0.001 compared with the value from OVA group.
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FIGURE 7. HspX-treated DCs pulsed with HPV 16-E7 protects mice against TC-1 tumor challenge. Mice were s.c. challenged with 33 105 TC-1 tumor
cells into the right flank area. For administration of DCs (1 3 106 cells/mouse), mice were i.v. injected with PBS, DCs, E7-DCs, or HspX-E7-DCs on days
1, 3, and 5 after the tumor challenge. (A) Following tumor challenge with TC-1 cells, tumor growth was monitored by measuring the diameter every 2 d.
p , 0.001, HspX-E7-DCs versus E7-DCs groups (n = 10 per group). (B) Survival of mice with TC-1 tumor challenge after injection of PBS, DCs, E7-DCs,
or HspX-E7-DCs (n = 10 mice per group). The p value was calculated by the Kaplan–Meier log-rank test between two groups of mice injected with E7-DCs
and HspX-E7-DCs. (C) On day 20 post challenge with TC-1 tumor cells, splenocytes were isolated and analyzed for the expression of CD62L and CD44 on
CD8+ T cells. The percentage of positive cells is shown for each panel. Bar graphs show the mean percentage 6 SEM of CD62L+ and CD44+ on CD8+
T cells (n = 3). **p, 0.05, ***p, 0.001. (D) In vivo CTL activity. C57BL/6 mice were primed with PBS, immature DCs, E7-DCs, (Figure legend continues)
1242 MYCOBACTERIUM TUBERCULOSIS HspX FOR CANCER VACCINE
 at Y
onsei M
edical Library on D
ecem
ber 8, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
proinflammatory cytokines such as TNF-a, IL-6, and IL-1 in DCs
as a result of the MyD88-dependent and TRIF-dependent path-
ways. We proved that MyD88 activated MAPKs, NF-kB, and
PI3K/PDK1/Akt pathways through adaptation with IRAK4. In
addition, phosphorylation of IRF3, a well-known downstream
molecule of TRIF, showed an increase in HspX-treated DCs. Our
results suggest that both intracellular adapters, namely, MyD88
and TRIF, are involved in mediating proinflammatory cytokine
production in HspX-treated DCs.
To test the adjuvant effect of HspX, we performed in vivo CTL
assays using the HPV-16 E7 Ag. This Ag is functionally required
for the initiation and maintenance of both precursor and invasive
lesions in cervical cancer (21). The percentage of target cell lysis
in mice that received HspX-E7-DCs (54%) was significantly
higher than that in mice that received PBS (0%), DCs (0.1%), or
E7-DCs (22%). Similar to the in vivo CTL activities that used the
HPV-16 E7 peptide, systemic administration of HspX-E7-DCs
induced a remarkable suppression of tumor growth. Using the
same model, we observed that the antitumor activity of HspX
originated from the marked increase in IFN-g production in the
T cells primed by DCs stimulated with HspX in the draining LNs.
We also noted an increase in the number of functional Ag-specific
CTLs, and increased numbers of activated CD8+ T cells (CD62Llow
CD44high). Therefore, HspX influenced the function of DCs in
multiple ways, and we suggest that it is an effective adjuvant for
DC-based antitumor immunotherapy against cervical cancer.
We examined whether the tumor-killing effect of CD8+ T cells
activated by HspX-E7-DCs also occurred in vivo using the CTL
activity assay. CTLs from mice injected with E7-DCs efficiently
lysed E7-pulsed splenocytes (target cells); however, CTLs from
or HspX-E7-DCs on days 1 and 7. At 7 d after boosting, CTL activity was determined by challenge with CFSEhigh E7 peptide–loaded splenocytes. Number
indicates the percentage of specific killing. A representative experiment (n = 4) is shown.
FIGURE 8. HspX-treated DCs pulsed with HPV 16-E7 inhibit B16-BL6 pulmonary metastasis. Mice were i.v. challenged with 3 3 105 B16-BL6
melanoma tumor cells. (A) For administration of DCs (1 3 106 cells per mouse), mice were s.c. injected into their hind leg footpad with PBS, DCs, TL-
pulsed DCs, or HspX-treated DCs pulsed with TL (HspX-TL-DCs) on days 1, 3, and 7 after tumor challenge. (B) For administration of DCs (1 3 106 cells
per mouse), mice were s.c. injected into their hind leg footpad with PBS, DCs, DCs pulsed with TRP2 peptide (TRP2-DCs), or HspX-treated DCs pulsed
with TRP2 peptide (HspX-TRP2-DCs) on days 1, 3, and 7 after the tumor challenge. At 1 wk after the final immunization, the metastatic nodules in their
lungs were counted. Bar graphs show the mean 6 SEM of the formation number of metastatic nodules from 10 mice. *p , 0.05, ***p , 0.001.
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mice injected with PBS or DCs could not efficiently lyse the target
cells (Figure 6D). In addition, CTLs from mice injected with
HspX-E7-DCs were able to lyse a significantly higher number of
target cells than the CTLs from mice injected with E7-DCs
(Figure 6D). These results indicate that DCs activated by HspX
could induce an antitumor immune response via activating CD8+
T cell–mediated cytotoxic activity against cervical tumors.
Furthermore, we demonstrated that HspX is an effective adjuvant
for antitumor vaccination using an invivo cervical cancer model. The
adjuvant increased the production of activated memory CD8+ T cells
in the spleen when HspX was used during E7 Ag recognition in
DCs. The activated memory T cells induced and maintained the
CTL activity specifically against the cancer expressing the E7 Ag.
DC vaccination with the adjuvant HspX, compared with vaccination
with only DCs, reduced the size of the cervical cancer and increased
the survival rate.
Immunotherapy with vaccination can be more effective in the
treatment of metastatic cancer, which is impossible to surgically
remove. Metastatic cancers in the lung induced by the injection of
B16-BL6 melanoma in mice were repressed by immunization with
DCs that overexpressed the melanoma-associated Ag human gp100
(22). Similarly, we found that the injection of recognized DCs
with tumor Ags reduced the extent of metastatic melanoma in the
lungs. Furthermore, HspX potentiated the inhibitory effect of DCs
when it stimulated the DCs as an adjuvant during Ag recognition.
We also found that immunization with DCs stimulated with the Ag
and/or HspX reduced regulatory T cell levels in the tumor and
spleen (see Supplemental Fig. 3), which resulted in augmented
cancer immunosurveillance. The mechanisms involved in the ef-
fect of DC immunization on the population of regulatory T cells
require further investigation.
Immunotherapeutic designs based on DCs in cancer treatment
are shifting to the development of more defined and safer vaccines.
This has concomitantly created a growing demand for the use of
immunopotentiators in DC-based immunotherapy, which are in-
trinsically poorly immunotargeted tumor Ags. In addition to facil-
itating the increased uptake of Ag by DCs, new immunoadjuvants
are designed to facilitate the recruitment and activation of DCs
by stimulating pattern recognition receptors, thereby enabling the
transition from the innate to specific-adaptive immune system for
tumor Ag–targeted T cell responses. Compared with earlier adju-
vants, HspX has many advantages regarding safety, the optimal Th1
type T cell immunity, and dosage for ex vivo DC activation. HspX
is clinically safe and defined, as it has been included in the BCG
vaccines for several decades. Therefore, it has an advantage over
other TLR4 agonists in drug development.
For example, monophosphoryl lipid A (MPLA) is a detoxified
derivative of LPS from Salmonella minnesota, and is the first of
a new generation of defined vaccine adjuvants to achieve widespread
use in human populations since the approval of alum (23). Although
LPS is highly toxic and causes strong inflammatory responses (24),
the LPS derivative MPLA enhances adaptive immunity without
causing excessive inflammation. The mechanism by which MPLA
enables potent but safe adjuvanticity appears to be a result of biased
TRIF signaling and selective activation of p38 MAPK (25). How-
ever, TRIF-biased TLR4 activation by MPLA may not produce
the greatest Th1 immune response. Indeed, MyD88 and TRIF
synergistic interactions are required for Th1 cell polarization by
a TLR4-based adjuvant. As engagement of both the MyD88 and
TRIF signaling pathways is essential for the effective adjuvant ac-
tivity of HspX-mediated TLR4 activation, HspX is able to boost
Ag-specific immunity elicited by DC-directed tumor Ags by sig-
naling MyD88 and TRIF. In addition, our previous studies dem-
onstrated that 5–10 mg/ml of recombinant mycobacterial Ags with
properties of TLR 2 or 4 agonists were required for optimal DC
activation. By contrast, 500 ng/ml of HspX is sufficient for the
functional activation of DCs.
In conclusion, we have shown that HspX is a potent and selective
agonist of TLR4 and is highly effective in the induction of tumor-
targeted Th1-type T cell immunity in DC-based cancer immuno-
therapy, using in vitro and in vivo models. The considerable effect of
HspX as an immunoadjuvant will open avenues for the development
of new immunotherapeutic strategies for better clinical outcomes.
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